Transcriptomic Analysis of Papillary Thyroid Cancer: A Focus on Immune-Subtyping, Oncogenic Fusion, and Recurrence
Clinical and Experimental Otorhinolaryngology · 31.05.2022 · 15 (2) · 183-193
DOI: 10.21053/ceo.2021.02215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Otorhinolaryngology, erschienen am 31.05.2022. Verfasst von Seung-Jin Park und 18 weiteren Autor:innen. Beteiligte Einrichtung: Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Ministry of Trade, Industry, and Energy.
Abstract (Originalsprache)
Objectives
Thyroid cancer is the most common endocrine tumor, with rapidly increasing incidence worldwide. However, its transcriptomic characteristics associated with immunological signatures, driver fusions, and recurrence markers remain unclear. We aimed to investigate the transcriptomic characteristics of advanced papillary thyroid cancer.
Methods
This study included 282 papillary thyroid cancer tumor samples and 155 normal samples from Chungnam National University Hospital and Seoul National University Hospital. Transcriptomic quantification was determined by high-throughput RNA sequencing. We investigated the associations of clinical parameters and molecular signatures using RNA sequencing. We validated predictive biomarkers using the Cancer Genome Atlas database.
Results
Through a comparison of differentially expressed genes, gene sets, and pathways in papillary thyroid cancer compared to normal tumor-adjacent tissue, we found increased immune signaling associated with cytokines or T cells and decreased thyroid hormone synthetic pathways. In addition, patients with recurrence presented increased CD8+ T-cell and Th1-cell signatures. Interestingly, we found differentially overexpressed genes related to immune-escape signaling such as CTLA4, IDO1, LAG3, and PDCD1 in advanced papillary thyroid cancer with a low thyroid differentiation score. Fusion analysis showed that the PI3K and mitogen-activated protein kinase (MAPK) signaling pathways were regulated differently according to the RET fusion partner genes (CCDC6 or NCOA4). Finally, we identified HOXD9 as a novel molecular biomarker that predicts the recurrence of thyroid cancer in addition to known risk factors (tumor size, lymph node metastasis, and extrathyroidal extension).
Conclusion
We identified a high association with immune-escape signaling in the immune-hot group with aggressive clinical characteristics among Korean thyroid cancer patients. Moreover, RET fusion differentially regulated PI3K and MAPK signaling depending on the partner gene of RET, and HOXD9 was found to be a recurrence marker for advanced papillary thyroid cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea.
- Department of Bioscience, University of Science and Technology, Daejeon, Korea.
- Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
- Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine, Seoul, Korea.
- Department of Pathology, Chungnam National University College of Medicine, Daejeon, Korea.
Förderung
- Ministry of Trade, Industry, and Energy
Zitieren
APA
Park, S. J., Kang, Y. E., Kim, J. H., Park, J. L., Kim, S. K., Baek, S. W., Chu, I. S., Yi, S., Lee, S. E., Park, Y. J., Chung, E. J., Kim, J. M., Ko, H. M., Kim, J. R., Jung, S. N., Won, H. R., Chang, J. W., Koo, B. S., & Kim, S. Y. (2022). Transcriptomic Analysis of Papillary Thyroid Cancer: A Focus on Immune-Subtyping, Oncogenic Fusion, and Recurrence. Clinical and Experimental Otorhinolaryngology, 15(2), 183-193. https://doi.org/10.21053/ceo.2021.02215
Vancouver
Park SJ, Kang YE, Kim JH, Park JL, Kim SK, Baek SW, et al. Transcriptomic Analysis of Papillary Thyroid Cancer: A Focus on Immune-Subtyping, Oncogenic Fusion, and Recurrence. Clinical and Experimental Otorhinolaryngology. 2022;15(2):183-193. doi:10.21053/ceo.2021.02215
BibTeX
@article{Park2022,
author = {Park, Seung-Jin and Kang, Yea Eun and Kim, Jeong-Hwan and Park, Jong-Lyul and Kim, Seon-Kyu and Baek, Seung-Woo and Chu, In Sun and Yi, Shinae and Lee, Seong Eun and Park, Young Joo and Chung, Eun-Jae and Kim, Jin Man and Ko, Hye Mi and Kim, Je-Ryong and Jung, Seung-Nam and Won, Ho-Ryun and Chang, Jae Won and Koo, Bon Seok and Kim, Seon-Young},
title = {Transcriptomic Analysis of Papillary Thyroid Cancer: A Focus on Immune-Subtyping, Oncogenic Fusion, and Recurrence},
journal = {Clinical and Experimental Otorhinolaryngology},
year = {2022},
volume = {15},
number = {2},
pages = {183--193},
doi = {10.21053/ceo.2021.02215}
}
EUVIMED